Payments to Medical Institutions, Healthcare Professionals, etc.
Chugai discloses information in accordance with Transparency Guidelines for Chugai Activities Involving Medical Institutions, etc., to ensure the transparency of its activities with medical institutions and thereby demonstrate to the wider community that its corporate activities are based on high ethical and moral standards.
Funding provided to Japanese medical institutions and healthcare professionals for each fiscal year (January 1 to December 31) is disclosed in the following five categories:A. Research and development expenses, etc., B. Academic research support expenses, C. Manuscript/writing fees, etc., D. Information provision-related expenses, and E. other expenses.
Fiscal Year 2020
A. Research and development expenses, etc.
Research and development expenses, etc. include expenses required for research/surveillance, etc. conducted under public regulations and various policies such as the Clinical Trials Act and GCP/GVP/GPSP ordinances under the Pharmaceutical and Medical Device Act. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.
| Category | Total annual transfer of value |
|---|---|
| Expenses for specified clinical traials | 295,004,550 |
| Research expenses based on ethical guidelines | 637,467,710 drug 90.4g |
| Non-clinical research expenses | 1,833,312,376 drug 2607.8g active ingredients/reagent 6867.99mg |
| Clinical trial expenses | 5,562,778,010 |
| Post-marketing clinical study expenses | 159,056,596 |
| Adverse drug reaction and infection case reporting expenses | 7,718,042 |
| Post-marketing surveillance expenses | 63,939,290 |
| Other expenses | 887,625,954 |
B. Academic research support expenses
Scholarship donations and general donations for promotion of academic research or research support, etc., and donations to academic societies, etc. and expenses of co-sponsored conferences, etc., as expenses to academic societies, etc. for supporting conferences. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.
| Category | Number of donations | Total for fiscal year |
|---|---|---|
| Scholarship donations | 1,555 | 1,350,500,000 |
| General donations | 86 | 504,588,000 |
| Donations to academic societies | - | 87,582,050 |
| Academic society co-hosting expenses | - | 317,936,976 |
C. Manuscript/writing fees, etc.
Fees, etc. for provision of scientific information, etc. on the company’s pharmaceutical products, medicine, and pharmacy or fees, etc. paid as consideration for lectures and writing or supervision of the manuscript that are related to research and development, or commissioning of services including consulting contracts, etc. Funds, etc. provided shall be disclosed as follows together with the annual total amount of each item.
| Category | Number of payments for fiscal year | Total for fiscal year |
|---|---|---|
| Lecturer honoraria | 5,485 | 415,571,226 |
| Manuscript writing and editorial supervision fees | 543 | 38,969,378 |
| Other outsourcing expenses | 2,497 | 221,538,195 |
D. Information provision-related expenses
Expenses of lecture meetings and explanation meetings, etc. for providing information, etc. related to the company’s pharmaceutical products, medicine and pharmacy to medical professionals.
| Category | Number of payments for fiscal year | Total for fiscal year |
|---|---|---|
| Expenses for lecture meetings and other meetings | 5,589 | 1,420,127,367 |
| Briefing expenses | 8,370 | 180,231,362 |
| Expenses for providing medical and pharmaceutical literature and other goods | - | 161,101,599 |
E. Other expenses
Expenses for hospitality, etc. as social courtesy
| Category | Total for fiscal year |
|---|---|
| Hospitality expenses | 15,966,996 |
